DNMT1 and acute myeloid leukemia: Recent studies have demonstrated that DNMT inhibitors like azacitidine and decitabine can enhance tumor antigen presentation and potentially sensitize AML cells to immune checkpoint inhibitors, particularly in elderly AML patients who are ineligible for intensive chemotherapy, reopening new avenues for combination strategies (Chiappinelli et al., 2015; Skrbic et al., 2021).